Fatty acid amide hydrolase (FAAH), an intracellular serine hydrolase enzyme, participates in
the deactivation of fatty acid ethanolamides such as the endogenous cannabinoid anandamide,
the intestinal satiety factor oleoylethanolamide, and the peripheral analgesic and anti-inflammatory factor palmitoylethanolamide. In the present study, we report on the design,
synthesis, and structure−activity relationships (SAR) of a novel class of potent, selective, and
systemically active inhibitors of FAAH activity, which we have recently shown to exert potent
anxiolytic-like effects in rats. These compounds are characterized by a carbamic template
substituted with alkyl or aryl groups at their O- and N-termini. Most compounds inhibit FAAH,
but not several other serine hydrolases, with potencies that depend on the size and shape of
the substituents. Initial SAR investigations suggested that the requirements for optimal potency
are a lipophilic N-alkyl substituent (such as n-butyl or cyclohexyl) and a bent O-aryl substituent.
Furthermore, the carbamic group is essential for activity. A 3D-QSAR analysis on the
alkylcarbamic acid aryl esters showed that the size and shape of the O-aryl moiety are correlated
with FAAH inhibitory potency. A CoMSIA model was constructed, indicating that whereas
the steric occupation of an area corresponding to the meta position of an O-phenyl ring improves
potency, a region of low steric tolerance on the enzyme active site exists corresponding to the
para position of the same ring. The bent shape of the O-aryl moieties that best fit the enzyme
surface closely resembles the folded conformations observed in the complexes of unsaturated
fatty acids with different proteins. URB524 (N-cyclohexylcarbamic acid biphenyl-3-yl ester,
9g) is the most potent compound of the series (IC50 = 63 nM) and was therefore selected for
further optimization.